Literature DB >> 8100746

B cell activation in clinically quiescent systemic lupus erythematosus (SLE) is related to immunoglobulin levels, but not to levels of anti-dsDNA, nor to concurrent T cell activation.

P E Spronk1, B T vd Gun, P C Limburg, C G Kallenberg.   

Abstract

In clinically quiescent SLE hypergammaglobulinaemia, presence of autoantibodies, and increased soluble IL-2 receptors (sIL-2R) have been reported, suggesting persistent B as well as T cell activation. In contrast, the primary immune response to test antigens is markedly decreased. To analyse these phenomena at a cellular level, we undertook a cross-sectional study on 13 non-active SLE patients and 15 controls. We determined the composition of lymphocyte subsets with special attention to activation markers (CD25, HLA-DR, CD38) and the presence of naive T cells (CD45RO-), and related those findings to serological parameters. In non-active SLE patients the expression of activation markers on B cells and T cells was higher than in normal controls (P < or = 0.02), but was not interrelated. Percentages of activated B cells in SLE were related to levels of total IgG (P < 0.02) and IgM (P < 0.02) but not to anti-dsDNA, suggesting a disordered immune system also in clinically quiescent SLE. Numbers of CD4+ cells (P < 0.001) and CD4+CD45RO- cells (P < 0.05) were decreased. The latter finding might explain the anergy to primary test antigens in clinically quiescent SLE.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8100746      PMCID: PMC1554751          DOI: 10.1111/j.1365-2249.1993.tb06494.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

Review 1.  Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology.

Authors:  E M Tan
Journal:  Adv Immunol       Date:  1989       Impact factor: 3.543

2.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

Authors:  C Bombardier; D D Gladman; M B Urowitz; D Caron; C H Chang
Journal:  Arthritis Rheum       Date:  1992-06

3.  Soluble CD8 during T cell activation.

Authors:  B E Tomkinson; M C Brown; S H Ip; S Carrabis; J L Sullivan
Journal:  J Immunol       Date:  1989-04-01       Impact factor: 5.422

4.  Rises in anti-double stranded DNA antibody levels prior to exacerbations of systemic lupus erythematosus are not merely due to polyclonal B cell activation.

Authors:  E J ter Borg; G Horst; E Hummel; P C Limburg; C G Kallenberg
Journal:  Clin Immunol Immunopathol       Date:  1991-04

5.  Decreased number of peripheral blood CD4 + CD29+ lymphocytes and increased in vitro spontaneous production of anti-DNA antibodies in patients with active systemic lupus erythematosus.

Authors:  R Gorla; P Airò; F Franceschini; E Stefani; S Braga; A Tincani; R Cattaneo
Journal:  J Rheumatol       Date:  1990-08       Impact factor: 4.666

6.  Increased soluble CD4 and decreased soluble CD8 molecules in patients with Sjögren's syndrome.

Authors:  S Sawada; S Sugai; S Iijima; M Takei; E Paredes; T Hayama; S Nishinarita; Y Hosokawa; T Horie; T Obara
Journal:  Am J Med       Date:  1992-02       Impact factor: 4.965

7.  A long-term immunological study of childhood onset systemic lupus erythematosus.

Authors:  C K Ting; K H Hsieh
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

8.  Immune deficiency in uremia: interleukin-2 production and responsiveness and interleukin-2 receptor expression and release.

Authors:  D Donati; D Degiannis; L Homer; L Gastaldi; J Raskova; K Raska
Journal:  Nephron       Date:  1991       Impact factor: 2.847

Review 9.  CD8+ lymphocytes from patients with systemic lupus erythematosus sustain, rather than suppress, spontaneous polyclonal IgG production and synergize with CD4+ cells to support autoantibody synthesis.

Authors:  M Linker-Israeli; F P Quismorio; D A Horwitz
Journal:  Arthritis Rheum       Date:  1990-08

10.  Autoantibodies specific for different isoforms of CD45 in systemic lupus erythematosus.

Authors:  T Mimura; P Fernsten; W Jarjour; J B Winfield
Journal:  J Exp Med       Date:  1990-08-01       Impact factor: 14.307

View more
  12 in total

Review 1.  Cytokines and systemic lupus erythematosus.

Authors:  G S Dean; J Tyrrell-Price; E Crawley; D A Isenberg
Journal:  Ann Rheum Dis       Date:  2000-04       Impact factor: 19.103

2.  The effect of interleukin-10 and of interleukin-12 on the in vitro production of anti-double-stranded DNA antibodies from patients with systemic lupus erythematosus.

Authors:  J Tyrrell-Price; P M Lydyard; D A Isenberg
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

3.  Expression of IL-2R, IL-4R, IL-6R on peripheral blood lymphocytes in systemic lupus erythematosus and correlation with disease activity: a prospective study.

Authors:  E Y Chan; C S Lau; H Zola
Journal:  J Clin Pathol       Date:  1996-08       Impact factor: 3.411

4.  Functional activation of lymphocyte CD44 in peripheral blood is a marker of autoimmune disease activity.

Authors:  P Estess; H C DeGrendele; V Pascual; M H Siegelman
Journal:  J Clin Invest       Date:  1998-09-15       Impact factor: 14.808

5.  HLA-DR expression on lymphocyte subsets as a marker of disease activity in patients with systemic lupus erythematosus.

Authors:  J F Viallard; C Bloch-Michel; M Neau-Cransac; J L Taupin; S Garrigue; V Miossec; P Mercie; J L Pellegrin; J F Moreau
Journal:  Clin Exp Immunol       Date:  2001-09       Impact factor: 4.330

6.  TSPAN33 is a novel marker of activated and malignant B cells.

Authors:  Van Phi Luu; Peter Hevezi; Felipe Vences-Catalan; José Luis Maravillas-Montero; Clayton Alexander White; Paolo Casali; Luis Llorente; Juan Jakez-Ocampo; Guadalupe Lima; Natalia Vilches-Cisneros; Juan Pablo Flores-Gutiérrez; Leopoldo Santos-Argumedo; Albert Zlotnik
Journal:  Clin Immunol       Date:  2013-08-15       Impact factor: 3.969

7.  Changes in levels of soluble T-cell activation markers, sIL-2R, sCD4 and sCD8, in relation to disease exacerbations in patients with systemic lupus erythematosus: a prospective study.

Authors:  P E Spronk; E J ter Borg; M G Huitema; P C Limburg; C G Kallenberg
Journal:  Ann Rheum Dis       Date:  1994-04       Impact factor: 19.103

8.  Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk.

Authors:  M Bijl; G Horst; H Bootsma; P C Limburg; C G M Kallenberg
Journal:  Ann Rheum Dis       Date:  2003-06       Impact factor: 19.103

9.  Perturbations of peripheral B lymphocyte homoeostasis in children with systemic lupus erythematosus.

Authors:  M Odendahl; R Keitzer; U Wahn; F Hiepe; A Radbruch; T Dörner; R Bunikowski
Journal:  Ann Rheum Dis       Date:  2003-09       Impact factor: 19.103

10.  Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study.

Authors:  P E Spronk; H Bootsma; M G Huitema; P C Limburg; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1994-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.